Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2010-02-05 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces an operating revenue of 7.7 million euros for the year 2009.
Earnings Release Classification · 98% confidence The document is a press release dated February 5, 2010, announcing the 'OPERATING REVENUE OF 7.7 MILLION EUROS FOR 2009' and providing key financial figures (turnover, government funding) for the fiscal year ended December 31, 2009, along with cash position details. This format, focusing on key financial highlights for a completed period (annual), strongly indicates an Earnings Release (ER). It is not the full Annual Report (10-K) as it explicitly states it uses 'IFRS unaudited provisional data' and is presented as a brief announcement, not the comprehensive filing itself. It is too detailed for just a Report Publication Announcement (RPA) and contains specific financial results, making ER the most appropriate classification. FY 2009
2010-02-05 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce des produits opérationnels de 7,7 millions d’euros en 2009
Earnings Release Classification · 99% confidence The document is a press release dated February 5, 2010, announcing operational revenue figures for the fiscal year 2009 (and Q4 2009) under IFRS standards. It presents key financial highlights (revenue, operational income, cash position, debt) but explicitly states the data is 'provisoire' (provisional) and 'non auditée' (unaudited). This format, focusing on key period results announced via press release, strongly aligns with an Earnings Release (ER). It is too brief and preliminary to be a full Annual Report (10-K) or a comprehensive Interim Report (IR). It is not a transcript (CT), management discussion (MDA), or a formal audit report (AR). FY 2009
2010-02-05 French
Nouveau nombre d’actions et de droits de vote et situation de trésorerie d’INNATE PHARMA au 31 décembre 2009
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated January 8, 2010, titled 'NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE ET SITUATION DE TRÉSORERIE D'INNATE PHARMA AU 31 DÉCEMBRE 2009' (New Number of Shares and Voting Rights and Cash Position as of December 31, 2009). It explicitly states the total number of shares and voting rights following a capital increase, referencing French commercial code and AMF regulations (L. 233-8 II du Code de Commerce et 223-16 du règlement général de l'Autorité des marchés financiers). It also mentions the cash position and rectifies the date of the upcoming Annual General Meeting. The core content is a mandatory regulatory disclosure regarding the capital structure and voting rights, which falls under general regulatory announcements or specific capital/share changes. Since it reports the final count of shares and voting rights after a capital operation, it strongly aligns with 'Share Issue/Capital Change' (SHA). However, it also contains a notification about the AGM date change. Given the primary focus on the updated share count and voting rights following a capital increase, SHA is the most precise fit, although it shares characteristics with a general regulatory filing (RNS). Since the document details the result of a capital change ('Suite à l'augmentation de capital...'), SHA is preferred over the general RNS.
2010-01-08 French
Number of shares and voting rights and cash situation of INNATE PHARMA as at December 31, 2009
Share Issue/Capital Change Classification · 95% confidence The document is titled "NUMBER OF SHARES AND VOTING RIGHTS AND CASH SITUATION OF INNATE PHARMA AS AT DECEMBER 31, 2009" and is dated January 8, 2010. It explicitly states that pursuant to French regulations (AMF charter), the company is updating its total number of shares outstanding and voting rights as of December 31, 2009. This content—reporting on the total share count and voting rights—is a specific regulatory disclosure often required periodically. While it mentions future events (AGM date, 2009 turnover announcement), the core purpose of this specific release is the mandated disclosure of share structure and cash position. This type of mandatory disclosure regarding share capital changes or structure updates fits best under 'Share Issue/Capital Change' (SHA) or potentially 'Regulatory Filings' (RNS). Given the focus on the total number of shares and voting rights following a capital increase, SHA is the most precise fit, as it relates directly to the capital structure. It is not a general earnings release (ER), an interim report (IR), or a director's dealing report (DIRS).
2010-01-08 English
Bilan semestriel du contrat de liquidité INNATE PHARMA avec la société NATIXIS SECURITIES
Regulatory Filings Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ INNATE PHARMA AVEC LA SOCIÉTÉ NATIXIS SECURITIES" (Semi-annual balance sheet of the liquidity contract) and provides a snapshot of the liquidity contract holdings (shares and cash) as of December 31, 2009. This type of periodic disclosure regarding market operations, specifically related to liquidity management or share transactions, aligns closely with filings concerning capital structure changes or specific regulatory disclosures. Since it details the status of a liquidity contract (which often involves share transactions or capital management), it fits best under Capital/Financing Update (CAP) or potentially Transaction in Own Shares (POS) if the liquidity contract is primarily for stabilization. However, given the context of a 'Bilan Semestriel' (Semi-annual balance sheet) related to a liquidity contract, it is a specific financial/capital structure update. It is not a full annual report (10-K), an earnings release (ER), or a standard dividend notice (DIV). It is a specific update on a financial arrangement. Comparing the options, 'CAP' (Capital/Financing Update) is the most appropriate category for updates on financing arrangements like liquidity contracts, although 'POS' (Transaction in Own Shares) is also related. Given the focus on the *balance* of the contract, 'CAP' is chosen as the broader category for financing structure updates. The document is short and appears to be a press release announcing the status, not a comprehensive report.
2010-01-08 French
Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES
Capital/Financing Update Classification · 99% confidence The document is titled "HALF-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH NATIXIS SECURITIES" and provides specific figures related to a liquidity contract as of December 31, 2009. This is a specific financial disclosure related to a short period (half-year) but is not a comprehensive financial report like a 10-K or a standard Interim Report (IR) which usually contains full balance sheets and income statements. It is a specific contractual update. Given the options, it is a specific financial disclosure. Since it relates to a short period (half-year) but focuses on a specific contract detail rather than the full financial statements, it doesn't perfectly fit 'IR' (Interim Report) or 'ER' (Earnings Release). However, it is a formal report detailing financial/contractual status for a period shorter than a year. If it were a comprehensive report, 'IR' would be appropriate. Since it is a very specific, short update on a liquidity contract referencing the end of the period, and it is presented as a press release/notice, it fits best under a specific financial notice category. Given the available codes, 'IR' (Interim / Quarterly Report) is the closest fit for a half-year financial status update, even if narrowly focused, as it reports on the status at the end of a half-year period. Alternatively, as a specific contractual notice, it could be 'RNS' (Regulatory Filings) if it's not comprehensive enough for 'IR'. Considering the explicit mention of 'HALF-YEAR REPORT', 'IR' is the most appropriate classification for periodic financial reporting shorter than annual.
2010-01-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.